BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
Subscribe To Our Newsletter & Stay Updated